Recent Updates
Recently added Catalysts
CTMX Positive Sentiment

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Tuesday, June 18, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CytomX Therapeutics, Inc. announced that CEO Sean McCarthy will participate in a fireside chat at the 2nd Annual Immune Cell Engager Virtual Conference on June 25, 2024. The presentation will include a live webcast accessible via the company's website. Additionally, CytomX management will hold one-on-one meetings with registered investors attending the conference.
Price reaction · baseline $1.37 (2024-06-17 close) · hit after-hours · clean, no other CTMX news in the window
day 0 close
-5.8%
day 1 · peak
-6.6%
day 3
-2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a notable industry conference
  • Live webcast available for wider audience access
  • Opportunity for investor engagement through one-on-one meetings

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
6.8%
average across 7 past catalysts
Cash runway
~54 mo
Minimal dilution risk
Lead asset
CX-2009
Phase 2 · Neoplasms

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET.
A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference.
About CytomX Therapeutics
Chief Financial Officer
Precision AQ (formerly Stern Investor Relations)

Frequently Asked Questions

What is CytomX Therapeutics known for?

CytomX Therapeutics specializes in masked, conditionally activated biologic therapeutics.

Who will speak at the H.C. Wainwright conference?

Sean McCarthy, D.Phil., CEO and chairman, will speak at the conference.

When is the H.C. Wainwright conference?

The conference takes place on June 25, 2024, at 2:00 p.m. ET.

Where can I watch the live webcast?

The live webcast will be available on CytomX's Events and Presentations page.

Will there be investor meetings at the event?

Yes, management will hold one-on-one meetings with registered investors.

ShareAdd on Google
Tags: CTMX Viatris Investor Conferences Healthcare CytomX immune cell engagers H.C. Wainwright virtual conference biologics
Last updated: Jun 18, 2024

Biotech snapshot

Cash runway
$330M liquidity · $6M/mo burn
~54 mo
Minimal dilution risk
Lead asset
CX-2009Phase 2
Neoplasms →

Catalyst track record

+53%
best trade around CTMX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for CTMX.

See every catalyst's timing & PoA →